March 16, 2026
The life sciences sector continues to show strong manufacturing and partnership activity in March 2026, with multiple announcements across pharma, biotech, and CDMO organisations confirming ongoing investment in biologics, sterile manufacturing, and specialty production. These developments are contributing to sustained hiring demand across the United States and the United Kingdom, particularly in manufacturing, quality, validation, and technical operations.
As pipelines grow and companies prepare for commercial production, expansion activity remains one of the main drivers of recruitment across the industry.
Recent industry updates show that companies are continuing to invest in biologics manufacturing, sterile fill-finish capacity, and advanced therapy production. These areas remain a priority due to the increasing number of biologic drugs, cell and gene therapies, and high-potency products moving through development and into commercial supply.
To support this growth, organisations are building new facilities, upgrading existing sites, and increasing their use of contract development and manufacturing organisations (CDMOs). Flexible manufacturing sites and modular production capabilities are also becoming more common as companies look to scale more efficiently.
Because of this, there is ongoing demand for experienced professionals with GMP, biologics, and sterile manufacturing experience across both the US and UK markets.
Alongside facility expansion, partnership and outsourcing activity remains high. Pharma and biotech companies continue to rely on CDMOs for clinical manufacturing, commercial production, fill-finish services, tech transfer, and validation support.
Outsourcing is often used to manage pipeline growth, reduce timelines, and access specialised capabilities that may not be available internally. This trend has been consistent throughout the past year and continues into 2026, particularly in biologics, advanced therapies, and specialty pharmaceuticals.
As a result, CDMOs across the US and UK are continuing to expand capacity, which is creating additional hiring demand across production, engineering, quality, and regulatory functions.
Recent announcements linked to site expansion, technology investment, and new production programmes are contributing to increased hiring across multiple areas of the life sciences industry.
The most in-demand skill sets currently include manufacturing, QA and QC, validation, technical operations, engineering, and regulatory compliance. Candidates with experience in GMP environments, biologics production, sterile processing, and scale-up activities remain particularly sought after.
Hiring demand is also being supported by the need to replace retiring staff, support new product launches, and prepare facilities for future pipeline growth.
Industry forecasts suggest that manufacturing expansion and outsourcing activity will continue through the rest of 2026 as companies invest in advanced therapies, biologics production, sterile capacity, and more flexible manufacturing networks.
With development pipelines remaining strong and regulatory approvals expected to increase in several therapy areas, the need for experienced life sciences professionals is likely to remain high across both the United States and the United Kingdom.
For companies, this means competition for talent will continue. For candidates, it means strong opportunities across manufacturing, technical, and quality functions.
© All rights reserved